Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01830621 | BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma | completed | Phase 3 | 282 | NCIC Clinical Trials GroupNETWORK | 3 | Aug 28, 2023 | clinicaltrials |
| NCT02031939 | Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer | unknown | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT01011478 | Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery | terminated | Phase 3 | 406 | NSABP Foundation IncNETWORK | 2 | Aug 16, 2023 | clinicaltrials |
| NCT05984485 | The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer(TaLaR-02) | recruiting | Phase 3 | 766 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT00079066 | Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer | completed | Phase 3 | 572 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 4, 2023 | clinicaltrials |
| NCT00640471 | Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer | completed | Phase 3 | 750 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT04262635 | Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer(C-CLASSIC) | unknown | Phase 3 | 80 | Sun Yat-sen UniversityOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT03950154 | Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer | unknown | Phase 3 | 198 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05948072 | Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM | unknown | Phase 3 | 250 | Fudan UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | terminated | Phase 3 | 355 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Jul 6, 2023 | clinicaltrials |
| NCT00979680 | Sphincter-preserving Surgery After Preoperative Treatment of Ultra-low Rectal Carcinoma(GRECCAR1) | completed | Phase 3 | 207 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00002525 | Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed | terminated | Phase 3 | 859 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT00003057 | Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer | completed | Phase 3 | 500 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04233151 | QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety | unknown | Phase 3 | 590 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT05797467 | Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients | recruiting | Phase 3 | 366 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05861505 | COLLISION RELAPSE Trial | recruiting | Phase 3 | 360 | Amsterdam UMC, location VUmcOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT02974556 | Proactive Management of Endoperitoneal Spread in Colonic Cancer(PROMENADE) | unknown | Phase 3 | 140 | University of Roma La SapienzaOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04087421 | Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome | recruiting | Phase 3 | 114 | University of AarhusOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05815082 | ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer | recruiting | Phase 3 | 490 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT00202774 | Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer | completed | Phase 3 | 348 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT01718873 | Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer(OBELICS) | completed | Phase 3 | 230 | National Cancer Institute, NaplesOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03391934 | Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer | unknown | Phase 3 | 234 | CinnagenINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05797077 | Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA | recruiting | Phase 3 | 346 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03742596 | Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients | withdrawn | Phase 2 / Phase 3 | 0 | King Hussein Cancer CenterOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | withdrawn | Phase 2 / Phase 3 | 0 | Portola PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT03678428 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | terminated | Phase 3 | 92 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05698082 | FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues | unknown | Phase 2 / Phase 3 | 120 | xiaoliang HuangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05699746 | CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD | not yet recruiting | Phase 3 | 38 | Zhejiang UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03231722 | First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS(TRIPLETE) | completed | Phase 3 | 435 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05236972 | PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer | recruiting | Phase 3 | 323 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT00642577 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer. | completed | Phase 3 | 214 | Hoffmann-La RocheINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT02870582 | Donafenib for Previously Treated Metastatic Colorectal Cancer | completed | Phase 3 | 536 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT00113763 | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 463 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT00364013 | PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy | completed | Phase 3 | 1,183 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT01099449 | Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy | completed | Phase 3 | 362 | Alliance for Clinical Trials in OncologyOTHER | 2 | Nov 3, 2022 | clinicaltrials |
| NCT03827044 | Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer(POLEM) | terminated | Phase 3 | 30 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT05427669 | Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)(AFFORD) | not yet recruiting | Phase 3 | 340 | Yanhong DengOTHER | 0 | Oct 7, 2022 | clinicaltrials |
| NCT00339183 | Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone | completed | Phase 3 | 1,186 | AmgenINDUSTRY | 0 | Sep 23, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT05540951 | VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer | unknown | Phase 3 | 78 | Fudan UniversityOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04389086 | Induction Chemotherapy for Locally Recurrent Rectal Cancer(PelvEx II) | recruiting | Phase 3 | 364 | Catharina Ziekenhuis EindhovenOTHER | 5 | Sep 6, 2022 | clinicaltrials |
| NCT01648894 | Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer(GRECCAR6) | completed | Phase 3 | 265 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03970694 | Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer | terminated | Phase 3 | 49 | Sun Yat-sen UniversityOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05409417 | Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT00389870 | Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil | completed | Phase 3 | 1,198 | University of LeedsOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05378867 | A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC(CRC) | unknown | Phase 3 | 126 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 0 | May 18, 2022 | clinicaltrials |
| NCT03475680 | Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery(COLONPREP) | terminated | Phase 3 | 193 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05374252 | Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients | unknown | Phase 3 | 102 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT05362617 | mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy | unknown | Phase 3 | 328 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02588248 | L-Menthol Injection as a Novel Technique During Colonoscopy(MINT-C) | terminated | Phase 3 | 82 | University Hospitals Cleveland Medical CenterOTHER | 1 | Apr 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2023source: clinicaltrials